Evidence map›Paper›PMID 38543852›Full record

ArticleVaccines2024

Antigen-Heterologous Vaccination Regimen Triggers Alternate Antibody Targeting in SARS-CoV-2-DNA-Vaccinated Mice.

Anders Frische, Karen Angeliki Krogfelt, Anders Fomsgaard, Ria Lassaunière

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Anders FrischeDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.ORCID 0000-0002-2841-7655
Karen Angeliki KrogfeltDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.ORCID 0000-0001-7536-3453
Anders FomsgaardDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.ORCID 0000-0003-4304-0603
Ria LassaunièreDepartment of Virus & Microbiological Special Diagnostics, Statens Serum Institut, 2300 Copenhagen, Denmark.ORCID 0000-0002-3910-7185
Statens Serum Institut · DK

Funding

Danish Ministry of Education and Research 0237-00006B
6 · The paper itself

Abstract

An in-depth analysis of antibody epitopes following vaccination with different regimens provides important insight for developing future vaccine strategies. B-cell epitopes conserved across virus variants may be ideal targets for vaccine-induced antibodies and therapeutic drugs. However, challenges lie in identifying these key antigenic regions, and directing the immune system to target them. We previously evaluated the immunogenicity of two candidate DNA vaccines encoding the unmodified spike protein of either the SARS-CoV-2 Index strain or the Beta variant of concern (VOC). As a follow-on study, we characterized here the antibody binding profiles of three groups of mice immunized with either the DNA vaccine encoding the SARS-CoV-2 Index strain spike protein only, the Beta VOC spike protein only, or a combination of both as an antigen-heterologous prime-boost regimen. The latter induced an antibody response targeting overlapping regions that were observed for the individual vaccines but with additional high levels of antibody directed against epitopes in the SD2 region and the HR2 region. These heterologous-vaccinated animals displayed improved neutralization breadth. We believe that a broad-focused vaccine regimen increases neutralization breadth, and that the in-depth analysis of B-cell epitope targeting used in this study can be applied in future vaccine research.

Indexed as

DNA vaccineepitope mappingmicroarrayneutralizing antibodiesSARS-CoV-2

Identifiers

PMID38543852
PMCPMC10974121
OpenAlexW4391970194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.